NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
28.17
-0.55 (-1.92%)
Apr 29, 2026, 10:54 AM EDT - Market open
Company Description
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V.
| Country | Netherlands |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Michael Davidson |
Contact Details
Address: Gooimeer 2-35 Naarden, 1411 DC Netherlands | |
| Phone | 31 35 206 2971 |
| Website | newamsterdampharma.com |
Stock Details
| Ticker Symbol | NAMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001936258 |
| ISIN Number | NL00150012L7 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | Chief Executive Officer, President and Executive Director |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board and Director |
| Mayur Amrat Somaiya | Chief Financial Officer |
| Douglas F. Kling | Chief Operating Officer |
| Louise Kooij | Chief Accounting Officer |
| Matthew Philippe | Executive Vice President &Head of Investor Relations |
| Bob Rambo | Executive Vice President of Marketing |
| Maryellen McQuade | Chief People Officer |
| Juliette Audet M.B.A., M.Sc. | Chief Strategy and Business Officer |
| Dr. Marc Ditmarsch M.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | 8-K | Current Report |
| Apr 20, 2026 | PRE 14A | Other preliminary proxy statements |
| Mar 11, 2026 | 144 | Filing |
| Mar 6, 2026 | 144 | Filing |
| Mar 5, 2026 | 144 | Filing |
| Mar 2, 2026 | 144 | Filing |
| Mar 2, 2026 | 8-K | Current Report |
| Feb 24, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |